BIOBIO-RAD LABORATORIES, INC.

NYSE bio-rad.com


$ 300.45 $ -0.04 (-0.01 %)    

Monday, 15-Apr-2024 15:59:56 EDT
QQQ $ 431.02 $ -7.21 (-1.65 %)
DIA $ 377.33 $ -2.56 (-0.67 %)
SPY $ 504.19 $ -6.40 (-1.25 %)
TLT $ 88.83 $ -1.40 (-1.55 %)
GLD $ 220.92 $ 4.06 (1.87 %)
$ 300.41
$ 303.94
$ 0.00 x 0
$ 0.00 x 0
$ 297.67 - $ 305.94
$ 261.59 - $ 489.36
167,913
na
8.77B
$ 0.84
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-16-2024 12-31-2023 10-K
2 10-27-2023 09-30-2023 10-Q
3 08-04-2023 06-30-2023 10-Q
4 05-05-2023 03-31-2023 10-Q
5 02-17-2023 12-31-2022 10-K
6 10-28-2022 09-30-2022 10-Q
7 07-29-2022 06-30-2022 10-Q
8 04-29-2022 03-31-2022 10-Q
9 02-11-2022 12-31-2021 10-K
10 10-29-2021 09-30-2021 10-Q
11 07-30-2021 06-30-2021 10-Q
12 04-30-2021 03-31-2021 10-Q
13 02-16-2021 12-31-2020 10-K
14 10-30-2020 09-30-2020 10-Q
15 07-31-2020 06-30-2020 10-Q
16 05-08-2020 03-31-2020 10-Q
17 03-02-2020 12-31-2019 10-K
18 11-01-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-10-2019 03-31-2019 10-Q
21 04-01-2019 12-31-2018 10-K
22 11-05-2018 09-30-2018 10-Q
23 08-09-2018 06-30-2018 10-Q
24 05-10-2018 03-31-2018 10-Q
25 04-16-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 03-01-2017 12-31-2016 10-K
30 11-02-2016 09-30-2016 10-Q
31 08-05-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 02-29-2016 12-31-2015 10-K
34 11-05-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-06-2015 03-31-2015 10-Q
37 03-02-2015 12-31-2014 10-K
38 11-07-2014 09-30-2014 10-Q
39 08-06-2014 06-30-2014 10-Q
40 05-08-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

The new product is expected to launch in Q2 2024 to a select group of academic transplant centers in the US and EU and more bro...

 bio-rad-laboratories-says-andrew-last-executive-vice-president-and-coo-is-planning-to-retire-by-early-september-of-2024

Last will remain part of Bio-Rad's executive leadership team to ensure a smooth transition while the company conducts a sea...

 citigroup-downgrades-bio-rad-laboratories-to-neutral-lowers-price-target-to-365

Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:BIO) from Buy to Neutral and lowers the price targe...

 tech-stocks-ease-on-hot-ppi-yields-rise-microsoft-amazon-snap-5-week-positive-streak-whats-driving-markets-friday

Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impactin...

 rbc-capital-maintains-outperform-on-bio-rad-laboratories-lowers-price-target-to-480

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:BIO) with a Outperform and lowers the price target f...

 applied-materials-posts-upbeat-earnings-joins-texas-roadhouse-vulcan-materials-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.

 bio-rad-laboratories-q4-2023-adj-eps-310-beats-282-estimate-sales-68120m-miss-68509m-estimate

Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $3.10 per share which beat the analyst consensus estimate of $2....

 earnings-scheduled-for-february-15-2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

 10-sp-500-stocks-with-over-40-upside-potential-hidden-gems-or-value-traps

S&P 500 index surges to new highs, driven by AI, earnings optimism, and Fed rate cuts. Top 10 stocks with significant upsid...

 sp-500s-hidden-gems-27-stocks-with-30-upside-potential-according-to-wall-street-analyst-targets

Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA...

 ubs-initiates-coverage-on-bio-rad-laboratories-with-buy-rating-announces-price-target-of-395

UBS analyst Dan Leonard initiates coverage on Bio-Rad Laboratories (NYSE:BIO) with a Buy rating and announces Price Target o...

 black-friday-on-wall-street-10-sp-500-stocks-trading-at-40-discount-from-analysts-expectations

Several S&P 500 stocks are trading at discounts of over 40% compared to analysts' price targets, offering potential ups...

 why-is-clinical-diagnostic-focused-bio-rad-stock-trading-lower-today

Bio-Rad Laboratories Inc (NYSE: BIO) shares are trading lower after the company lowered its annual revenue growth forecast, cit...

NEW CASE INVESTIGATION